CAB-101: A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This research is being done to determine the maximum dose of an investigational drug called autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) that can be safely given to patients with pemphigus vulgaris to target and kill only the B cells that are making the autoantibodies that attack DSG3.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 842584
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
